Radiographic pattern of progression of recurrent GBM treated with bevacizumab with or without irinotecan.

被引：0
|
作者：
Dory-Lautrec, P. [1 ]
Tabouret, E. [1 ]
Barrie, M. [1 ]
Boucard, C. [1 ]
Matta, M. [1 ]
Autran, D. [1 ]
Girard, N. [1 ]
Chinot, O. L. [1 ]
机构：
[1] Univ Hosp Timone, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2091
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2091
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab
    Vauleon, Elodie
    Mesbah, Habiba
    Gedouin, Daniel
    Lecouillard, Isabelle
    Louvel, Guillaume
    Hamlat, Abderrahmane
    Riffaud, Laurent
    Carsin, Beatrice
    Quillien, Veronique
    Audrain, Odile
    Lesimple, Thierry
    BULLETIN DU CANCER, 2012, 99 (02) : 121 - 126
  • [22] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
    Kreisl, Teri N.
    Kim, Lyndon
    Moore, Kraig
    Duic, Paul
    Royce, Cheryl
    Stroud, Irene
    Garren, Nancy
    Mackey, Megan
    Butman, John A.
    Camphausen, Kevin
    Park, John
    Albert, Paul S.
    Fine, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 740 - 745
  • [23] EFFICACY AND SAFETY OF BEVACIZUMAB (BV) AND IRINOTECAN (I) IN ELDERLY PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORM (GBM): A MONOCENTRIC RETROSPECTIVE STUDY
    Robert, M.
    Leux, C.
    Gourmelon, C.
    Campone, M.
    Frenel, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [24] Efficacy, toxicity, and pattern of response and progression in patients with high-grade gliomas treated with bevacizumab and irinotecan: Experience in one center.
    Gallardo Martin, E.
    Areses Manrique, M. C.
    Anido Herranz, U.
    Aguin Losada, S.
    Brozos Vazquez, E.
    Vieito Villar, M.
    Castro Gomez, J. E.
    Leon, L.
    Lamas, M. J.
    Lopez, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] PHASE II TRIAL OF SINGLE-AGENT BEVACIZUMAB FOLLOWED BY BEVACIZUMAB PLUS IRINOTECAN AT TUMOR PROGRESSION IN RECURRENT ANAPLASTIC GLIOMA
    Kreisl, Teri Nguyen
    Butman, John A.
    Hammoud, Dima
    Iwamoto, Fabio M.
    Kim, Lyndon
    Duic, Paul
    Albert, Paul
    Fine, Howard A.
    NEURO-ONCOLOGY, 2009, 11 (05) : 620 - 620
  • [26] Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan
    Haksoyler, Veysel
    A Besen, Ali
    Koseci, Tolga
    Olgun, Polat
    Bayram, Ertugrul
    Topkan, Erkan
    BIOMARKERS IN MEDICINE, 2021, 15 (11) : 851 - 859
  • [27] FDG-PET PREDICTS SURVIVAL IN RECURRENT HIGH GRADE GLIOMAS TREATED WITH BEVACIZUMAB AND IRINOTECAN
    Colavolpe, C.
    Chinot, O.
    Metellus, P.
    Mancini, J.
    Barrie, M.
    Bequet-Boucard, C.
    Tabouret, E.
    Mundler, O.
    Figarella-Branger, D.
    Guedj, E.
    NEURO-ONCOLOGY, 2012, 14 : 10 - 10
  • [28] Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment
    Sever, Ozlem Nuray
    Oktay, Kadir
    Guzel, Ebru
    Kaya, Vildan
    Guzel, Aslan
    Yildirim, Mustafa
    INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 91 - 95
  • [29] A RETROSPECTIVE REVIEW OF PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) TREATED WITH BEVACIZUMAB (AVASTIN), LOMUSTINE (CCNU) AND SIROLIMUS (RAPAMUNE)
    Ranjan, Tulika
    Peters, Katherine
    Vlahovic, Gordana
    Friedman, Henry
    Desjardins, Annick
    NEURO-ONCOLOGY, 2013, 15 : 127 - 127
  • [30] A SERIES OF PATIENTS (PTS) WITH RECURRENT GBM (rGBM) TREATED WITH ABT-414, BEVACIZUMAB (BEV) AND CCNU
    De Silva, Madhawa
    Lee, Adrian
    Kastela, Marina
    Wheeler, Helen
    Khasraw, Mustafa
    NEURO-ONCOLOGY, 2019, 21 : 19 - 19
12345